Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2019

View Archived Issues

Toughening up amyloid fibrils

New genetic alphabet doubles the fun

Cell Medica awarded grant for development of CAR-NK T-cell therapy

Correlation of immune characteristics with immune control and treatment efficacy in herpes labialis

Bayer presents novel adenosine A2B receptor antagonist with potential for lung fibrosis

Improved lymphocyte access via development of a lymphatic-targeted dosing system

Generation of a novel nucleoside inhibitor for the treatment of ischemia-reperfusion injury

Beactica, VIB and CD3 enter drug discovery alliance

Sarepta Therapeutics announces preliminary results from first cohort in phase I/II study of MYO-101

Foamix presents positive safety and efficacy data from phase III study of FMX-103

Double dose of suicide genes increases beta-cell safety, efficacy

Dual adenosine receptor A2A/A2B receptor antagonists described by Merck & Co.

C/EBPdelta identified as a therapeutic target for IVIG-resistant Kawasaki disease

Improved safety and efficacy of a second-generation diphtheria toxin-based fusion protein

CytomX Therapeutics gives program highlights for CX-072 and CX-2009

Eisai to support AAR Japan program to raise awareness of mycetoma in Sudan

Sunshine Lake Pharma identifies new semicarbazide-sensitive amine oxidase inhibitors

B7-H3.CAR-Ts demonstrate promising efficacy and safety in preclinical cancer models

New PI3Kgmma and PI3Kdelta inhibitors discovered at Columbia University

Nodthera patents NLRP3 inflammasome inhibitors

First patient dosed ORIENT-32 study of Tyvyt plus IBI-305 in HCC

Jiangsu Chia Tai Tianqing Pharmaceutical Group, Medshine Discovery present AR antagonists

Miransertib shows promising therapeutic efficacy in children with Proteus syndrome

NIAID is recruiting participants in phase I study of VRC-FLUNPF099-00-VP influenza vaccine

Acurx presents first-in-human data for ACX-362E

Novavax's phase III Prepare study of ResVax misses primary objective

Horizon Pharma reports phase III OPTIC study data for teprotumumab